Gattefosse SAS
Records under this name other than the patents Gattefosse SAS holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 4 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,531,193 | Use of an Acmella oleracea extract for the botulinum toxin-like effect thereof in an anti-wrinkle cosmetic composition Term ended Term ended Aug 9, 2025 · From the USPTO record | Term ended | Term ended Aug 9, 2025 | From the USPTO record |
| US 7,648,573 | Wetting agent based on a mixture of monoesters and diesters of butylene glycol Lapsed on the fee record Ended Jan 19, 2022 · From the USPTO record | Lapsed on the fee record | Ended Jan 19, 2022 | From the USPTO record |
| US 6,309,665 | Composition with sustained release of active principle, capable of forming a microemulsion Formerly held Term ended Term ended Feb 2, 2021 · From the USPTO record | Term ended | Term ended Feb 2, 2021 | From the USPTO record |
| US 6,312,704 | Orally administrable composition capable of providing enhanced bioavailability when ingested Formerly held Term ended Term ended Jan 18, 2020 · From the USPTO record | Term ended | Term ended Jan 18, 2020 | From the USPTO record |
| US 6,395,261 | Walnut seed meal extract Term ended Term ended Nov 26, 2019 · From the USPTO record | Term ended | Term ended Nov 26, 2019 | From the USPTO record |
| US 6,194,005 | Method for preparing a pharmaceutical composition with modified release of the active principle, comprising a matrix Formerly held Term ended Term ended Mar 23, 2019 · From the USPTO record | Term ended | Term ended Mar 23, 2019 | From the USPTO record |
| US 6,054,136 | Orally administrable composition capable of providing enhanced bioavailability when ingested Term ended Term ended Apr 11, 2017 · From the USPTO record | Term ended | Term ended Apr 11, 2017 | From the USPTO record |
| US 6,270,773 | Process for stabilizing vegetable plants Lapsed on the fee record Ended Aug 7, 2009 · From the USPTO record | Lapsed on the fee record | Ended Aug 7, 2009 | From the USPTO record |
| US 6,171,615 | Sustained release theophylline formulations, excipient systems and methods of production Lapsed on the fee record Ended Jan 9, 2009 · From the USPTO record | Lapsed on the fee record | Ended Jan 9, 2009 | From the USPTO record |
| US 6,379,700 | Process for manufacturing tablets for the sustained release of active principle(s) Formerly held Lapsed on the fee record Ended Apr 30, 2006 · From the USPTO record | Lapsed on the fee record | Ended Apr 30, 2006 | From the USPTO record |